Replies to post #200614 on Biotech Values

[mcbio]

NKTR -

I've mentioned it in a couple places but NKTR's most valuable asset a year from now could end up being their first immunotherapy candidate NKTR-214 (they also have a couple other in the pipeline). First patient data should come later this year.

Hadn't looked at NKTR in some time and didn't know they had an IO asset now. Looks like NKTR-214 is a CD122 agonist that activates IL-2. Who are the competitors targeting IL-2 in an IO setting and do you have any links to any general buzz on this approach? I'm always on the lookout for any new potential IO plays.